Why the study?
Does tinzaparin safely and effectively treat venous thromboembolism compared to unfractionated heparin or warfarin?
Does tinzaparin safely and effectively treat venous thromboembolism compared to unfractionated heparin or warfarin?
Tinzaparin is an effective and safe alternative to unfractionated heparin and warfarin for VTE treatment, with the advantage of not requiring dose adjustments in patients with moderate renal impairment or obesity.
Answers are grounded in this paper and cite their sources.
Supports tinzaparin consideration for VTE in moderate renal impairment or obesity; leaves open need for prospective RCTs before guideline updates.
Low molecular weight heparin (LMWH) has been widely used for the initial treatment of patients presenting with venous thromboembolism. The LMWH, tinzaparin, has been shown in randomised clinical trials to be as effective and safe as unfractionated heparin for the initial treatment of venous thromboembolism and in clinical trials, it has been used in place of warfarin for the long-term treatment of deep vein thrombosis. Tinzaparin can safely be given to patients with significant renal impairment (creatinine clearance of > or = 20 ml/min) and the dose of tinzaparin does not need to be altered in patients with a body mass index of > 25.
No takes yet. Share an insight, caveat, or question.
Pineo et al. (2003) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: